Zai Lab is an innovative, commercial-stage, global biopharmaceutical company. Leveraging both licenseinand self-development capability, the company currently has seven products being approved in China,including four oncology products (ZEJULA, OPTUNE GIO, QINLOCK, AUGTYRO), one immunologyproduct (efgartigimod), and two infectious disease products (NUZYRA, XACDURO). Meanwhile, it has anextensive new product pipeline covering oncology, immunology, neuroscience, and infectious diseasestreatment. Sales ramp-up o ...